苏州大学药学院欢迎您!

张秀莉

发布者:黄小波发布时间:2019-09-27浏览次数:22

姓  名:张秀莉
职称职务:特聘教授
电子邮箱:zhangxl@suda.edu.cn
办公地址:云轩楼1125


一、学习工作经历
1、学历背景:

1996.9-2000.7  南开大学,本科

2000.9-2007.2  中国科学院大连化学物理研究所,博士(硕博连读)

2、国外学习研究经历:

2003.4-2005.3:德国国家环境健康研究中心,进修


3、工作经历:
2007.03-2009.11  中国科学院大连化学物理研究所,助理研究员

2009.12-2013.06  中国科学院大连化学物理研究所,副研究员

2013.06-2019.04  中国科学院大连化学物理研究所,研究员

2019.05-至今     苏州大学医学部药学院中药系,特聘教授


二、研究方向
1.多维制备色谱技术用于天然产物药效物质基础研究

2.器官芯片技术/3D器官打印技术用于天然产物的毒效/药效评价

3.先进光学成像技术用于天然产物的毒效/药效评价


三、主要研究成果

发表论文104篇,其中SCI论文84篇,申请中国专利30项,授权中国专利1项,美国专利1项。先后主持国家自然科学基金面上基金、科技部国际合作、科学院个性化药物先导专项等项目,参加了国家自然科学基金重点基金,国家863计划和973项目。


1、近五年发表的论文(按时间倒序)

[1] X. You, X. Zhang, Y. Luo, L. Liu, W. Zhao, B. Lin, Establishment of 3D Organ Chip for Multiplexed Assessment of Type 2 Diabetes Drugs, Progress in Biochemistry and Biophysics, 46 (2019) 620-630.

[2] F. Xu, H. Zhou, X. Liu, X. Zhang, Z. Wang, T. Hou, J. Wang, L. Qu, P. Zhang, H. Piao, X. Liang, Label-free cell phenotypic study of FFA4 and FFA1 and discovery of novel agonists of FFA4 from natural products, Rsc Advances, 9 (2019) 15073-15083.

[3] J. Deng, X. Zhang, Z. Chen, Y. Luo, Y. Lu, T. Liu, Z. Wu, Y. Jin, W. Zhao, B. Lin, A cell lines derived microfluidic liver model for investigation of hepatotoxicity induced by drug-drug interaction, Biomicrofluidics, 13 (2019).

[4] J. Deng, Z. Chen, X. Zhang, Y. Luo, Z. Wu, Y. Lu, T. Liu, W. Zhao, B. Lin, A liver-chip-based alcoholic liver disease model featuring multi-non-parenchymal cells, Biomedical Microdevices, 21 (2019).

[5] W. Zhou, J. Wang, Y. Zhao, L. Yu, Y. Fang, H. Jin, H. Zhou, P. Zhang, Y. Liu, X. Zhang, X. Liang, Discovery of  β2-adrenoceptor agonists in Curcuma zedoaria Rosc using label-free cell phenotypic assay combined with two-dimensional liquid chromatography, Journal of Chromatography A, 1577 (2018) 59-65.

[6] Y. Zhang, Y. Liu, L. Wu, C. Fan, Z. Wang, X. Zhang, A. Alachkar, X. Liang, O. Civelli, Receptor-specific crosstalk between prostanoid E receptor 3 and bombesin receptor subtype 3, Faseb Journal, 32 (2018) 3184-3192.

[7] P. Zhang, J. Wang, Y. Zhao, X. Zhang, L. Qu, C. Wang, J. Feng, A. Wang, W. Zhou, Y. Liu, T. Hou, H. Zhou, Z. Wang, X. Liang, Discovery of novel antagonists on beta2-adrenoceptor from natural products using a label-free cell phenotypic assay, Naunyn-Schmiedeberg's archives of pharmacology, 391 (2018) 1411-1420.

[8] L. Wei, T. Hou, C. Lu, J. Wang, X. Zhang, Y. Fang, Y. Zhao, J. Feng, J. Li, L. Qu, H.-l. Piao, X. Liang, SAR Studies of N- 2-(1H-Tetrazol-5-yl)phenyl benzamide Derivatives as Potent G Protein-Coupled Receptor-35 Agonists, Acs Medicinal Chemistry Letters, 9 (2018) 422-427.

[9] J. Wang, H. Qi, X. Zhang, W. Si, F. Xu, T. Hou, H. Zhou, A. Wang, G. Li, Y. Liu, Y. Fang, H.-L. Piao, X. Liang, Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting beta-catenin signaling, Biomedicine & pharmacotherapy, 108 (2018) 724-733.

[10] Y. Luo, X.L. Zhang, Y.J. Li, J. Deng, X.R. Li, Y.Y. Qu, Y. Lu, T.J. Liu, Z.G. Gao, B.C. Lin, High-glucose 3D INS-1 cell model combined with a microfluidic circular concentration gradient generator for high throughput screening of drugs against type 2 diabetes, Rsc Advances, 8 (2018) 25409-25416.

[11] F. Yang, M.X. Zhao, X.L. Zhang, Q. Li, Y.S. Xiao, X. Ke, J. He, L. Ye, J.T. Feng, X.F. Hao, Z.H. Ke, X.M. Liang, Exploratory Purification of Compounds from Aqueous Extracts of Pinus massoniana Lamb. by Two-Dimensional Preparative Liquid Chromatography, Chromatographia, 80 (2017) 39-43.

[12] L. Wei, J.X. Wang, X.L. Zhang, P. Wang, Y.P. Zhao, J.Q. Li, T. Hou, L.L. Qu, L.Y. Shi, X.M. Liang, Y. Fang, Discovery of 2H-Chromen-2-one Derivatives as G Protein-Coupled Receptor-35 Agonists, Journal of Medicinal Chemistry, 60 (2017) 362-372.

[13] C. Fan, L.-H. Wu, G.-F. Zhang, F. Xu, S. Zhang, X. Zhang, L. Sun, Y. Yu, Y. Zhang, R.D. Ye, 4 '-Hydroxywogonin suppresses lipopolysaccharide-induced inflammatory responses in RAW 264.7 macrophages and acute lung injury mice, Plos One, 12 (2017).

[14] N. Du, Y. Liu, X. Zhang, J. Wang, J. Zhao, J. He, H. Zhou, L. Mei, X. Liang, Discovery of new muscarinic acetylcholine receptor antagonists from Scopolia tangutica, Scientific Reports, 7 (2017).

[15] Y. Zhang, Z. Long, Z. Guo, Z. Wang, X. Zhang, R.D. Ye, X. Liang, O. Civelli, Hydroxycinnamic acid amides from Scopolia tangutica inhibit the activity of M1 muscarinic acetylcholine receptor in vitro, Fitoterapia, 108 (2016) 9-12.

[16] Y. Zhang, H. Jin, X. Li, J. Zhao, X. Guo, J. Wang, Z. Guo, X. Zhang, Y. Tao, Y. Liu, D. Chen, X. Liang, Separation and characterization of bufadienolides in toad skin using two-dimensional normal-phase liquid chromatography x reversed-phase liquid chromatography coupled with mass spectrometry, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 1026 (2016) 67-74.

[17] L. Wang, Y. Zhang, Z. Wang, N. Gong, T.D. Kweon, B. Vo, C. Wang, X. Zhang, J.Y. Chung, A. Alachkar, X. Liang, D.Z. Luo, O. Civelli, The Antinociceptive Properties of the Corydalis yanhusuo Extract, Plos One, 11 (2016) e0162875.

[18] J. Wang, X. Zhang, X. Li, Y. Zhang, T. Hou, L. Wei, L. Qu, L. Shi, Y. Liu, L. Zou, X. Liang, Anti-gastric cancer activity in three-dimensional tumor spheroids of bufadienolides, Scientific Reports, 6 (2016) 24772-24781.

[19] J. Wang, X. Zhang, Y. Fang, X. Liang, Label-Free Cell Phenotypic Assays for Assessing Drug Polypharmacology, Current Pharmaceutical Design, 22 (2016) 3190-3200.

[20] H. Jin, Y. Liu, Z. Guo, J. Wang, X. Zhang, C. Wang, X. Liang, Recent development in liquid chromatography stationary phases for separation of Traditional Chinese Medicine components, Journal of Pharmaceutical and Biomedical Analysis, 130 (2016) 336-346.

[21] T. Hou, L. Shi, J. Wang, L. Wei, L. Qu, X. Zhang, X. Liang, Label-free cell phenotypic profiling and pathway deconvolution of neurotensin receptor-1, Pharmacological Research, 108 (2016) 39-45.

[22] J.X. Wang, T. Hou, L. Wei, L.Y. Shi, J. He, N. Zhou, G.W. Sun, X.L. Zhang, X.M. Liang, Discovery of new targets of phenolic acids in danshen using a label-free cell phenotypic assay, Rsc Advances, 5 (2015) 25768-25776.

[23] J.X. Wang, Z.M. Guo, A.J. Shen, L. Yu, Y.S. Xiao, X.Y. Xue, X.L. Zhang, X.M. Liang, Hydrophilic-subtraction model for the characterization and comparison of hydrophilic interaction liquid chromatography columns, Journal of Chromatography A, 1398 (2015) 29-46.

[24] H. Jin, J. Zhao, W. Zhou, A. Shen, F. Yang, Y. Liu, Z. Guo, X. Zhang, Y. Tao, X. Peng, X. Liang, Preparative separation of a challenging anthocyanin from Lycium ruthenicum Murr. by two-dimensional reversed-phase liquid chromatography/hydrophilic interaction chromatography, Rsc Advances, 5 (2015) 62134-62141.

[25] H. Jin, Y. Liu, F. Yang, J. Wang, D. Fu, X. Zhang, X. Peng, X. Liang, Characterization of anthocyanins in wild Lycium ruthenicum Murray by HPLC-DAD/QTOF-MS/MS, Analytical Methods, 7 (2015) 4947-4956.

[26] J. Ding, W. Wen, D. Xiang, P. Yin, Y. Liu, C. Liu, G. He, Z. Cheng, J. Yin, C. Sheng, W. Zhang, F. Nan, W. Ye, X. Zhang, H. Wang, psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling, Oncotarget, 6 (2015) 11627-11639.

[27] Y. Zhang, C. Wang, L. Wang, G.S. Parks, X. Zhang, Z. Guo, Y. Ke, K.-W. Li, M.K. Kim, B. Vo, E. Borrelli, G. Ge, L. Yang, Z. Wang, M.J. Garcia-Fuster, Z.D. Luo, X. Liang, O. Civelli, A Novel Analgesic Isolated from a Traditional Chinese Medicine, Current Biology, 24 (2014) 117-123.

[28] Y. Zhang, C. Wang, Z. Guo, X. Zhang, Z. Wang, X. Liang, O. Civelli, Discovery of N-methyltetrahydroprotoberberines with kappa-opioid receptor agonists-opioid receptor agonist activities from corydalis yanhusuo W. T. Wang by using two-dimensional liquid chromatography, Journal of Ethnopharmacology, 155 (2014) 1597-1602.

[29] X.L. Zhang, H.Y. Deng, Y.S. Xiao, X.Y. Xue, A.M. Ferrie, T. Elizabeth, X.M. Liang, Y. Fang, Label-free cell phenotypic profiling identifies pharmacologically active compounds in two traditional Chinese medicinal plants, Rsc Advances, 4 (2014) 26368-26377.

[30] J.X. Wang, C.R. Wang, Z.M. Guo, X.F. Dong, Y.S. Xiao, X.Y. Xue, X.L. Zhang, X.M. Liang, A novel method for characterization and comparison of reversed-phase column selectivity, Journal of Chromatography A, 1361 (2014) 153-161.

[31] J.X. Wang, S. Kong, J.Y. Yan, G.W. Jin, Z.M. Guo, A.J. Shen, J.Y. Xu, X.L. Zhang, L.J. Zou, X.M. Liang, Hydrophilic interaction liquid chromatography-solid phase extraction directly combined with protein precipitation for the determination of triptorelin in plasma, Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences, 960 (2014) 214-221.

[32] Z. Long, Y. Zhang, Z.M. Guo, L. Wang, X.Y. Xue, X.L. Zhang, S.S. Wang, Z.W. Wang, O. Civelli, X.M. Liang, Amide Alkaloids from Scopolia tangutica, Planta Medica, 80 (2014) 1124-1130.

[33] X.L. Li, Z.M. Guo, C.R. Wang, A.J. Shen, Y.F. Liu, X.L. Zhang, W.J. Zhao, X.M. Liang, Purification of bufadienolides from the skin of Bufo bufo gargarizans Cantor with positively charged C18 column, Journal of Pharmaceutical and Biomedical Analysis, 92 (2014) 105-113.

[34] C.M. Li, Y.Y. Zhao, Z.M. Guo, X.L. Zhang, X.Y. Xue, X.M. Liang, Effective 2D-RPLC/RPLC enrichment and separation of micro-components from Hedyotis diffusa Willd. and characterization by using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry, Journal of Pharmaceutical and Biomedical Analysis, 99 (2014) 35-44.

[35] X.J. Guo, X.L. Zhang, Z.M. Guo, Y.F. Liu, A.J. Shen, G.W. Jin, X.M. Liang, Hydrophilic interaction chromatography for selective separation of isomeric saponins, Journal of Chromatography A, 1325 (2014) 121-128.


2、课题

1.    国家自然科学基金面上项目,81473436,基于无标记动态质量重置技术的丹参多靶点作用研究,2015/01-2018/1271万元,结题,主持。

2.    科学院个性化药物先导专项, XDA12040314,基于无标记整合药理学的糖尿病先导化合物发现, 2016/01—2017/12100万元,结题,主持。

3.    国家科技合作与交流专项,2015DFG32260,基于本草物质组的三阴性乳腺癌靶向药物发现,2015/04-2017/1091万元,结题,主持。

4.    成都康弘制药有限公司,KH2YFX20121224,松龄血脉康物质基础探索性研究,2012/11-2015/4100万元,结题,主持。

5.    中国科学院知识创新工程重要方向项目,KSCX2-YW-R-214,中药寡糖及寡糖苷强极性物质纯化分离网络实验室,2009/10-2010/1220万元,结题,主持。

6.    国家自然科学青年基金,20805046 ,针对寡糖的亲水色谱材料及高效分离,2009/01-2011/1218万元,已结题,主持。

7.    国家自然科学基金重点基金,U1508221,基于新型无标记细胞筛选技术的辽宁道地药材药效物质基础研究,2016/1-2019/12280万元,在研,参加。

8.    国家自然科学基金重点基金,21135005,糖蛋白糖链结构的基础研究,2012/1-2016/12300万元,结题,参加。

9.     “十二五国家科技支撑计划项目,2012BAD33B03,功能食品设计及制造关键技术与产品,2012/01-2015/1250万元,结题,参加。

10.  国家重大科学研究计划(973计划)项目,2012CB910601,蛋白质定量新方法及相关技术研究,2012/01-2016/1286.5万元,结题,参加

11.  美国康宁公司,KH2YFX20110328,天然产物的系统药理学筛选,2011/6-2013/1220万美金,结题,参加。

12.  国家重大新药创制专项,2009ZX09301-012,辽宁省重大新药创制综合平台,2009/01-2010/12390万元,结题,参加。

13.  中国科学院国际合作局对外合作重点项目,121421KYSB20130013,天然化合物的高通量纯化分离与活性评价,2014/01—2016/1270万元,结题,参加。

14.  中国科学院知识创新工程重要方向项目,KSCX2-YW-R-170,植物天然产物分离分析分中心, 2009/10-2010/1260万元,结题,参加。

15.  国家科技合作与交流专项,2007DFC30550,中药抗抑郁活性成分的高通量制备与筛选,2007/09-2010/08200万元,结题,参加。

16.  国家自然科学基金面上项目,20775079,新型亲水作用色谱分离材料制备及其应用,2008/1-2010/12,27万元,结题,参加。


四、主要荣誉

第一届中国百篇最具影响优秀国际学术论文,2007年

“大连市自然科学学术成果学术论文”一等奖,2011年

“辽宁省自然科学学术成果学术论文”二等奖,2012年

中国科学院青年创新促进会,2012年

大连医科大学“14-16年度临床教学先进教育工作者”称号,2017年